Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase

Background There is growing awareness that tumour cells build up a “self-advantageous” microenvironment that reduces effectiveness of anti-tumour immune response. While many different immunosuppressive mechanisms are likely to come into play, recent evidence suggests that extracellular adenosine acting at A2A receptors may have a major role in down-modulating the immune response as cancerous tissues contain elevated levels of adenosine and adenosine break-down products. While there is no doubt that all cells possess plasma membrane adenosine transporters that mediate adenosine uptake and may also allow its release, it is now clear that most of extracellularly-generated adenosine originates from the catabolism of extracellular ATP. Methodology/Principal Findings Measurement of extracellular ATP is generally performed in cell supernatants by HPLC or soluble luciferin-luciferase assay, thus it generally turns out to be laborious and inaccurate. We have engineered a chimeric plasma membrane-targeted luciferase that allows in vivo real-time imaging of extracellular ATP. With this novel probe we have measured the ATP concentration within the tumour microenvironment of several experimentally-induced tumours. Conclusions/Significance Our results show that ATP in the tumour interstitium is in the hundrends micromolar range, while it is basically undetectable in healthy tissues. Here we show that a chimeric plasma membrane-targeted luciferase allows in vivo detection of high extracellular ATP concentration at tumour sites. On the contrary, tumour-free tissues show undetectable extracellular ATP levels. Extracellular ATP may be crucial for the tumour not only as a stimulus for growth but also as a source of an immunosuppressive agent such as adenosine. Our approach offers a new tool for the investigation of the biochemical composition of tumour milieu and for development of novel therapies based on the modulation of extracellular purine-based signalling.

[1]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[2]  S. Colgan,et al.  Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. , 2004, Blood.

[3]  H. Carlsen,et al.  In Vivo Imaging of NF-κB Activity1 , 2002, The Journal of Immunology.

[4]  M. Goldman,et al.  Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. , 2005, Blood.

[5]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[6]  R. Tarnuzzer,et al.  Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. , 1999, Circulation research.

[7]  N. Dale,et al.  Release of ATP in the central nervous system during systemic inflammation: real-time measurement in the hypothalamus of conscious rabbits , 2007, The Journal of physiology.

[8]  G. Dubyak,et al.  Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. , 1999, American journal of physiology. Cell physiology.

[9]  W. Schaper,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. , 1995, Brain research. Molecular brain research.

[10]  A. Marrogi,et al.  Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. , 2000, The Annals of thoracic surgery.

[11]  E. Vizi,et al.  Shaping of monocyte and macrophage function by adenosine receptors. , 2007, Pharmacology & therapeutics.

[12]  V. Kuchroo,et al.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.

[13]  Alexander V. Gourine,et al.  ATP is a mediator of chemosensory transduction in the central nervous system , 2005, Nature.

[14]  G. Lenz,et al.  In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model , 2006, BMC Cancer.

[15]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[16]  Manfred Thiel,et al.  Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. , 2004, Annual review of immunology.

[17]  T. Libermann,et al.  NTPDase and 5' ecto-nucleotidase expression profiles and the pattern of extracellular ATP metabolism in the Walker 256 tumor. , 2007, Biochimica et biophysica acta.

[18]  B B Fredholm,et al.  Adenosine, an endogenous distress signal, modulates tissue damage and repair , 2007, Cell Death and Differentiation.

[19]  T. Adair Growth regulation of the vascular system: an emerging role for adenosine. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[20]  A. Viola,et al.  Metabolic mechanisms of cancer-induced inhibition of immune responses. , 2007, Seminars in cancer biology.

[21]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[22]  A. Maggi,et al.  In vivo imaging of transcriptionally active estrogen receptors , 2003, Nature Medicine.

[23]  F. Di Virgilio,et al.  A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. , 2005, Molecular biology of the cell.

[24]  J. Wiley,et al.  Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. , 2006, Blood.

[25]  F. Di Virgilio Liaisons dangereuses: P2X(7) and the inflammasome. , 2007, Trends in pharmacological sciences.

[26]  F. Di Virgilio,et al.  Liaisons dangereuses: P2X(7) and the inflammasome. , 2007, Trends in pharmacological sciences.

[27]  Mina J Bissell,et al.  Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? , 2005, Cancer cell.

[28]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.